These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2292528)

  • 41. Effects of food intake and age on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. Comparison with cefpodoxime proxetil.
    Totsuka K; Shimizu K; Mori N; Sugihara T; Sakai A; Yamaji S; Michisuji Y; Shinohara Y; Kubo A; Tokuoka H
    Int J Antimicrob Agents; 2001 Nov; 18(5):463-9. PubMed ID: 11711262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil.
    Hughes GS; Heald DL; Patel R; Spillers CR; Batts DH; Euler AR
    Methods Find Exp Clin Pharmacol; 1990 Apr; 12(3):197-204. PubMed ID: 2352449
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice].
    Brambilla C; Benhamou D; Guérin JC; Kelkel E; Muir JF; Prud'homme A; Taytard A; Fauche A
    Pathol Biol (Paris); 1995 Nov; 43(9):815-24. PubMed ID: 8746104
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.
    Hughes GS; Heald DL; Barker KB; Patel RK; Spillers CR; Watts KC; Batts DH; Euler AR
    Clin Pharmacol Ther; 1989 Dec; 46(6):674-85. PubMed ID: 2557183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil.
    Hendrickson JR; North DS
    Ann Pharmacother; 1995 Jun; 29(6):561-5. PubMed ID: 7663025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
    Geddes AM
    Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses.
    Carrillo NA; Giguère S; Gronwall RR; Brown MP; Merritt KA; O'Kelley JJ
    Am J Vet Res; 2005 Jan; 66(1):30-5. PubMed ID: 15691032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
    Fujii R
    Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. Otitis Study Group.
    Asmar BI; Dajani AS; Del Beccaro MA; Mendelman PM
    Pediatrics; 1994 Dec; 94(6 Pt 1):847-52. PubMed ID: 7971000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
    Safran C
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():93-101. PubMed ID: 2292535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Laboratory and clinical studies of cefpodoxime proxetil in pediatric field].
    Nishimura T; Tabuki K; Aoki S; Takagi M
    Jpn J Antibiot; 1989 Jul; 42(7):1607-20. PubMed ID: 2810732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion.
    Nicolaos G; Crauste-Manciet S; Farinotti R; Brossard D
    Int J Pharm; 2003 Sep; 263(1-2):165-71. PubMed ID: 12954191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension.
    Gao Y; Qian S; Zhang J
    Chem Pharm Bull (Tokyo); 2010 Jul; 58(7):912-7. PubMed ID: 20606336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic study and clinical evaluation of cefpodoxime proxetil in the elderly with impaired renal function.
    Ishioka T
    J Chemother; 1995 Nov; 7 Suppl 4():122-3. PubMed ID: 8904130
    [No Abstract]   [Full Text] [Related]  

  • 56. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo.
    Chachaty E; Depitre C; Mario N; Bourneix C; Saulnier P; Corthier G; Andremont A
    Antimicrob Agents Chemother; 1992 Sep; 36(9):2009-13. PubMed ID: 1416894
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-a-day therapy of cefpodoxime proxetil for respiratory tract infections.
    Sawae Y; Ninomiya K; Sumida I; Inoue T; Takaki K; Okada K; Kumagai Y; Ishimaru T; Shimono N; Misumi H
    J Chemother; 1995 Nov; 7 Suppl 4():134-6. PubMed ID: 8904134
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical evaluation of a new oral cephem, cefpodoxime proxetil in children].
    Meguro H; Arimasu O; Shiraishi H; Tajima T; Hiruma F; Nishimura S; Sugie N; Sugamata K; Abe T; Fujii R
    Jpn J Antibiot; 1989 Jul; 42(7):1561-70. PubMed ID: 2810730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cefpodoxime proxetil in upper respiratory tract infections.
    Bergogne-Berezin E
    Drugs; 1991; 42 Suppl 3():25-33. PubMed ID: 1726205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
    Cox CE; Graveline JF; Luongo JM
    Drugs; 1991; 42 Suppl 3():41-50. PubMed ID: 1726207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.